Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| MaxLinear | Nokia | Pfizer | |
|---|---|---|---|
| Moat rating | none MaxLinear’s FY2025 10-K does not show a durable advantage. Its income statement reports revenue of $693,263 thousand in 2023, $360,528 thousand in 2024 and $467,641 thousand in 2025, with operating losses of $38,221 thousand, $223,352 thousand and $126,890 thousand. The risk factors say “Increased competition has resulted in price pressure, decreased demand, reduced revenue and profitability, and loss of market share”; the business section says competitors include “companies with much longer operating histories, greater name recognition, and substantially greater financial, technical and operational resources”; and because its products “often are building block semiconductors” it also faces integrated-circuit makers, “some of which may be existing customers or platform partners”. Two customers were 28% of 2025 net revenue and the ten largest 65%, and “substantially all of our sales to date have been made on a purchase order basis”. Gross profit held up - $385,663 thousand, $194,782 thousand and $265,814 thousand for 2023 to 2025 - and the AI optical ramp has lifted 2026 results, but a revenue base that nearly halved in one year and three straight years of operating losses do not evidence a moat. | narrow The advantage is narrow and confined to one small unit. In the FY2025 20-F (filed 2026-03-05), Nokia Technologies turned EUR 1 501m of net sales into EUR 1 059m of operating profit (70.6%) while the group earned EUR 885m on EUR 19 889m (4.4%) — licensing out-earned the whole company on 7.5% of sales. Mobile Networks ran a 2.8% margin, down 270bps from 5.5% in 2024, against risk factors citing "equipment price erosion and aggressive price competition". Nokia Technologies net sales fell 22% from EUR 1 928m and operating profit 30% on 2024 catch-up, yet it is not eroding: over EUR 800m of contracted recurring revenue runs through 2030 and Technology Standards grew 12% cc in H1'26. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | none No single source of advantage in the 10-K is strong enough to name. MaxLinear has “over one thousand issued patents” and says consideration under intellectual property sale agreements “has previously been and is currently expected in the future be material”, but the same filing describes its products as building blocks that larger vendors can integrate, says some optical-interconnect customers are “module makers who are vertically integrated, where we compete with internally supplied components”, and claims only that “We believe that we compete favorably” on factors from product performance to price. Its RF-CMOS integration know-how is real, but nothing in the filing shows customers locked in or rivals unable to match it. | intangibles ip The advantage is standard-essential cellular patents, and it lives in one unit. Nokia Technologies conducts "cellular, multimedia and WiFi research and standardization, protects Nokia's innovation by securing patents" and "monetizes Nokia's innovation through patent licensing", across "more than 26 000 families, including over 8 000 essential to 5G" and "more than 250 licensees" including Apple, Samsung and Mercedes-Benz. It is not network effects or switching costs: customers "may also consolidate their supplier base to our disadvantage - all the way to a one-supplier model". From 1 January 2026 the unit reports as Technology Standards inside Mobile Infrastructure. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | fast follower In its fastest-growing line MaxLinear is a second source. Deep Fundamental’s September 27, 2024 deep dive (https://deepfundamental.substack.com/p/deep-dive-optical-module-market) says “Marvell ($MRVL) and Broadcom ($AVGO) are two major suppliers of DSPs, with Marvell holding the top position in the market”, that “Coherent also sources heavily from Marvell, with Broadcom/ Maxlinear potentially serving as second supplier with 20-30% share”, and that MaxLinear offers “DSPs at about half the price of Marvell's if it can achieve a meaningful mass production volume of at least 100K units per month”. Keystone has since reached volume - management said on the Q2 2026 call that it “continues to ramp into high volume production at major hyperscale customers across U.S. and Asia” - but the 10-K names Broadcom, Qualcomm, Realtek, Skyworks, Credo, MediaTek, Marvell, MACOM, Texas Instruments, Analog Devices, Renesas, Microchip and Semtech as primary merchant competitors, and no third-party source found ranks MaxLinear first in any of its markets. | at parity Nokia is top-three almost everywhere and decisive only in slices. The 20-F reports that "Dell'Oro and Omdia ranked Nokia third in global Mobile RAN market share for the first three quarters", and Radio Networks is the largest single business unit (EUR 1 765m of EUR 4 815m group, Q2'26). It also holds #2 in global optical, #1 in IP edge routing and #1 in xPON OLT for a sixth year (Dell'Oro/Omdia Q3'25), while in data centers it competes "against large incumbent players" and calls expansion "challenging". 2025 segment sales were Network Infrastructure EUR 7 986m vs Mobile Networks EUR 7 806m; the Q2'26 6-K shows Optical +20%, IP +16% cc, AI & Cloud EUR 446m vs 220m, Radio +7%. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate Mixed. Gross profit has stayed in proportion through the cycle - the 10-K’s income statement shows $265,814 thousand on revenue of $467,641 thousand in 2025 - and the Q2 2026 release (https://www.sec.gov/Archives/edgar/data/0001288469/000128846926000050/a06302026exhibit991.htm) reports GAAP gross margin of 57.8% against 56.5% a year earlier, guiding Q3 to 57.0%-60.0%. But the 10-K says “From time to time, we have reduced the average unit price of our products due to competitive pricing pressures, new product introductions by us or our competitors, and for other reasons, and we expect that we will have to do so again in the future”, that under some distributor agreements “we provide protection for reductions in selling prices of the distributors' inventory”, and in optical DSPs it entered as the lower-priced challenger. | weak Pricing power is weak at the consolidated grain, in the filing's own words. The 20-F risk factors describe a market "characterized by maturing industry technologies... equipment price erosion and aggressive price competition", customers "reverting to vendors to compensate" for their own unit-revenue erosion, and warn Nokia "may increasingly be required to agree to less favorable contractual terms in order to remain competitive". Group operating margin was 4.4% in 2025. This band covers equipment, ~92% of sales, not licensing, whose FRAND-bound royalties ran a 70.6% margin; supply-tight optical is our inference, not filing text. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | MaxLinear is a fabless designer of RF, analog and mixed-signal communications SoCs whose core skill, per its FY2025 10-K, is combining broadband RF and analog front ends with digital signal processing in standard CMOS. It sells into broadband access (cable, fiber PON and DSL gateways - approximately 44% of 2025 net revenue), home connectivity (Wi-Fi, MoCA, G.hn and Ethernet), wired and wireless infrastructure including optical data-center DSPs, and industrial and multi-market interface and power products. After a downturn that took revenue from $693,263 thousand in 2023 to $360,528 thousand in 2024, the AI optical ramp is turning it around: the Q2 2026 release reports revenue of $168,847 thousand, up 55% year over year, with the infrastructure business up 145% on the Keystone PAM4 DSP ramp for 800G, and management raised its 2026 optical data-center revenue outlook to $210 million-$230 million on the call. The moat question is whether that growth rests on anything durable. In optical DSPs MaxLinear entered as a lower-priced second source to Marvell; elsewhere it competes with Broadcom, Qualcomm, Realtek and MediaTek, which can integrate the functions it sells; customers are concentrated; and the 10-K still carries the Silicon Motion arbitration over its terminated merger, whose outcome it says it cannot predict. On this record MaxLinear is a technically capable challenger without a moat. | Nokia's moat is real but small and segment-bound. Per the FY2025 Form 20-F (filed 2026-03-05; Nokia files a 20-F, not a 10-K), the cellular SEP portfolio — 26 000+ patent families, 8 000+ declared essential to 5G, 250+ licensees, EUR 800m+ annual contracted recurring revenue through 2030 — produced a 70.6% operating margin on EUR 1 501m of sales and out-earned the entire group (EUR 885m). Everything else is competitive equipment: group operating margin 4.4%, Mobile Networks 2.8% (-270bps), with the filing's own risk factors describing price erosion, less favorable contract terms and customers consolidating "all the way to a one-supplier model". Rankings are per-line (#3 RAN, #2 optical, #1 IP edge routing, #1 xPON OLT; Dell'Oro/Omdia Q3'25), never company-wide. Q2/H1'26 figures come from the 23 Jul 2026 6-K: sec.gov/Archives/edgar/data/924613/000110465926086081/tm2621179d1_6k.htm | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | MaxLinear sells chips, much of it through Asian distributors, ODMs and module makers - products shipped to Asia were 82% of 2025 net revenue, including 49% to Hong Kong - that build cable modems, PON terminals, Wi-Fi gateways, base-station radios and optical transceivers for operators and hyperscale data centers. In the AI chain it sits beside the optical-module makers as a DSP supplier, competing with Marvell and Broadcom and, at vertically integrated module makers, with internally supplied components. | — | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |